Showing 1,277 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Boosted darunavir plus lamivudine matches three-drug regimen

News
8 August 2017
The search for a cure

VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment

News
2 August 2017
New & experimental HIV treatments

Long-acting NRTI shows promise for HIV treatment and PrEP

News
2 August 2017
New & experimental HIV treatments

First protease inhibitor combination pill maintains viral suppression

News
1 August 2017
New & experimental HIV treatments

Doravirine combination pill looks good for initial HIV treatment

News
27 July 2017
New & experimental HIV treatments

New integrase inhibitor bictegravir works well for first-line HIV treatment

News
25 July 2017
New & experimental HIV treatments

Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks

News
24 July 2017
New & experimental HIV treatments

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

Editor's pick
Business Wire
21 July 2017
New & experimental HIV treatments

The 2017 Pipeline Report

Editor's pick
Treatment Action Group
19 July 2017
Access to healthcare

Dolutegavir access in the Asia-Pacific region

Editor's pick
amfAR Treat Asia
27 June 2017
New & experimental HIV treatments

ViiV Healthcare Files Regulatory Submissions for First Two-Drug HIV Maintenance Regimen

Editor's pick
ViiV
2 June 2017
Pharmaceutical industry

Gilead and GSK go head-to-head with similar HIV drug data

Editor's pick
Reuters
31 May 2017
New & experimental HIV treatments

Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies

Editor's pick
Gilead press release
30 May 2017
New & experimental HIV treatments

Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union

Editor's pick
Merck press release
22 May 2017
Pharmaceutical industry

CHMP recommends for approval generic version of Atripla

Editor's pick
EATG
22 May 2017
Pharmaceutical industry

Gilead's last chronic HIV drug — and what it plans to do now

Editor's pick
San Francisco Business Times
11 May 2017
New & experimental HIV treatments

Orphan Drug Designation for CytoDyn's PRO 140 Declined by the FDA

Editor's pick
Cytodyn press release
18 April 2017
New & experimental HIV treatments

Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide

News
27 March 2017
The search for a cure

Research helps explain how vedolizumab antibody therapy leads to sustained viral remission

News
23 March 2017
New & experimental HIV treatments

Several new candidates in HIV drug pipeline discussed at conference

News
15 March 2017
Cardiovascular disease

New antibody therapy “profoundly” successful at reducing inflammation from HIV

Editor's pick
BETA blog
9 March 2017
New & experimental HIV treatments

Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good

News
9 March 2017
Treatment guidelines

Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

Editor's pick
NHS England
6 March 2017
New & experimental HIV treatments

New HIV capsid inhibitors show high potency and prolonged activity in early studies

News
3 March 2017